Zomedica Pharmaceuticals Corp (ZOM)

NYSE
Currency in USD
0.0382
+0.0058(+17.90%)
Real-time Data·
Showing Zomedica Pharma historical data. For real-time data please try another search
Fair Value
Day's Range
0.03150.0419
52 wk Range
0.01510.1952
Key Statistics
Edit
Prev. Close
0.0975
Open
0.032
Day's Range
0.0315-0.0419
52 wk Range
0.0151-0.1952
Volume
7.35M
Average Volume (3m)
8.49M
1-Year Change
-72.66%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ZOM Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
0.0000
Downside
-100.00%
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.
Show more

Zomedica Pharma Company Profile

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system. It provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan.

Zomedica Pharmaceuticals Corp Earnings Call Summary for Q4/2024

  • Q4 2024 revenue up 8% YoY to $7.9M; full-year revenue hit record $27.3M despite $7.2M net loss
  • Strong cash position of $71.4M; gross margin at 70.3%, exceeding target range of 65-70%
  • Stock surged 17.9% post-earnings; company aims for cash flow breakeven at $50M run rate
  • Expanding into equine market and international territories; monthly investor webinars planned
  • Management exploring options to enhance share price; addressing NYSE delisting concerns
Last Updated: 14-03-2025, 03:26 am
Read Full Transcript

Compare ZOM to Peers and Sector

Metrics to compare
ZOM
Peers
Sector
Relationship
P/E Ratio
0.0x0.0x0.0x
PEG Ratio
0.000.000.00
Price/Book
0.0x0.0x0.0x
Price / LTM Sales
0.0x0.0x0.0x
Upside (Analyst Target)
0.0%0.0%0.0%
Fair Value Upside
Unlock0.0%0.0%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 0.0000

Earnings

Latest Release
May 08, 2025
EPS / Forecast
-- / -0.01
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.